Historique
Article de Périodique
Chemsex practice in France: an update in Addictovigilance data (2022)
Auteur(s) :
BATISSE, A. ;
EIDEN, C. ;
DEHEUL, S. ;
MONZON, E. ;
DJEZZAR, S. ;
PEYRIERE, H.
Année
2022
Page(s) :
397-404
Langue(s) :
Anglais
Refs biblio. :
26
Domaine :
Drogues illicites / Illicit drugs
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus géographique
FRANCE
Thésaurus mots-clés
ADDICTOVIGILANCE
;
CHEMSEX
;
DROGUES DE SYNTHESE
;
CATHINONES
;
EPIDEMIOLOGIE
;
HSH
;
EVOLUTION
;
PROFIL SOCIO-DEMOGRAPHIQUE
;
EFFET SECONDAIRE
;
SURVEILLANCE EPIDEMIOLOGIQUE
Résumé :
BACKGROUND: Complications related to Chemsex practice (consumption of psychoactive substances in sexual context) were first assessed by the French Addictovigilance Network in 2014. In response to the deaths reported in 2016, a new expert report was commissioned to update the complications and evolution of Chemsex-related practices in France.
METHODS: Between January 2008 and August 2017, all Chemsex cases collected through the French Addictovigilance Network's epidemiological tools were analyzed. Comparison of data between two periods (before and after 2014) was performed to assess the evolution of practices.
RESULTS: Over the entire survey period, 235 Chemsex cases were identified, all of them in men, with a mean ± SD age of 39 ± 11 years, including 24 deaths (10.2%). An increase in the number of reported cases was observed from one in 2008 to 50 in the first eight months of 2017. The main medical histories include human immunodeficiency virus (HIV; 45%) and hepatitis C (20%) infections, and substance use disorders (36%). In those 235 cases, 345 psychoactive substances were identified, mainly cathinones. Polydrug use was reported in 75% of cases. The main complications were substance use disorders (63%), acute neurological or cardiovascular intoxications (50%), various psychiatric disorders (39%), and viral and bacterial infections (18%). Gamma-Butyrolactone (GBL) was present in 95% of comas. An increase in the number of deaths was observed during the survey period.
CONCLUSION: The French Addictovigilance Network, via this pharmacoepidemiological surveillance, warns public health authorities in order to support harm reduction programs and the management of Chemsexers.
METHODS: Between January 2008 and August 2017, all Chemsex cases collected through the French Addictovigilance Network's epidemiological tools were analyzed. Comparison of data between two periods (before and after 2014) was performed to assess the evolution of practices.
RESULTS: Over the entire survey period, 235 Chemsex cases were identified, all of them in men, with a mean ± SD age of 39 ± 11 years, including 24 deaths (10.2%). An increase in the number of reported cases was observed from one in 2008 to 50 in the first eight months of 2017. The main medical histories include human immunodeficiency virus (HIV; 45%) and hepatitis C (20%) infections, and substance use disorders (36%). In those 235 cases, 345 psychoactive substances were identified, mainly cathinones. Polydrug use was reported in 75% of cases. The main complications were substance use disorders (63%), acute neurological or cardiovascular intoxications (50%), various psychiatric disorders (39%), and viral and bacterial infections (18%). Gamma-Butyrolactone (GBL) was present in 95% of comas. An increase in the number of deaths was observed during the survey period.
CONCLUSION: The French Addictovigilance Network, via this pharmacoepidemiological surveillance, warns public health authorities in order to support harm reduction programs and the management of Chemsexers.
Affiliation :
Addictovigilance center, Fernand-Widal Hospital Paris, France